Literature DB >> 15251335

Effect of colchicine on cyclosporine nephrotoxicity, reduction of TGF-beta overexpression, apoptosis, and oxidative damage: an experimental animal study.

U Disel1, S Paydas, A Dogan, G Gulfiliz, S Yavuz.   

Abstract

BACKGROUND: Proinflamatory and profibrotic cytokines may be responsible for the cyclosporine A nephrotoxicity. Increased levels of apoptosis, free oxygen redicals, and transforming growth factor beta (TGF-beta), may play an important roles in the pathogenesis of nephrotoxicity. In this experimental animal study, we sought to investigate the effects of colchicine on the cyclosporine nephrotoxicity.
METHOD: Twenty-four Wistar albino rats were divided into three groups: cyclosporine 15 mg/kg subcutaneously (SC); cyclosporine 15 mg/kg SC plus colchicine 30 mcg/kg orally; and a control group; equal doses of olive oil orally were administered to groups 1, 2, and 3. Renal function, cyclosporine levels, and serum malonyldialdehyde (MDA) levels were measured at the end of 4 weeks. Apoptosis, TGF-beta, and other findings were detected in renal tissue with the TUNEL method, with a immunohistochemical method, and with routine staining procedures, respectively.
RESULTS: There were significant differences in the values of mean creatinine clearance between group 1 and group 3 and between group 2 and group 3 (P < .05 for each comparison), but not between group 1 and group 2 (P > .05). MDA levels in group 1 were high compared with the control group (P < .05) with a trend toward elevation relative to group 2 but the results were not statistically significant (P > .05). Renal tubular vacuolization in group 1 and group 2 animal were greater than in the control group, but no significant difference were observed between any of the groups (P > .05). Mononuclear cell infiltration in group 1 and group 2 hosts were higher than the control group, but there was no significant differences between the groups (P > .05). Afferent arteriolar hyalinization was observed group 1 and 2 but not group 3. There was a statistically significant difference between group 1 and group 3 and between group 2 and group 3 (P < .05 for each comparison). The expression level of TGF-beta was higher in group 1 than group 2 or group 3 (P <.05 for each comparison) but group 2 and group 3 were similar (P > .05). Apoptotic cell death count of group 1 was higher than that in group 2 or group 3 (P < .05, for each comparison); moreover, group 2 also showed greater numbers of apoptotic cells than group 3 (P < .001). At the end of the 4 weeks, there was no intersititial fibrosis in any of the hosts.
CONCLUSION: While cyclosporine caused increased TGF-beta expression and apoptotic cell death in the renal tissue of rats colchicine prevented the increase in MDA serum levels, TGF-beta expression, and apoptosis in renal tissue. Our study suggests that colchicine may diminish the cyclosporine nephrotoxicity by its suppressing the expression of TGF-beta, apoptotic cell death, and MDA production. Copyright 2004 Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15251335     DOI: 10.1016/j.transproceed.2004.05.078

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  10 in total

1.  Melamine induces Ca2+-sensing receptor activation and elicits apoptosis in proximal tubular cells.

Authors:  Allen J Yiu; Cliff-Lawrence Ibeh; Sanjit K Roy; Bidhan C Bandyopadhyay
Journal:  Am J Physiol Cell Physiol       Date:  2017-04-05       Impact factor: 4.249

2.  Inflammatory choroidal neovascularization.

Authors:  Piergiorgi Neri; Marta Lettieri; Cinzia Fortuna; Mara Manoni; Alfonso Giovannini
Journal:  Middle East Afr J Ophthalmol       Date:  2009-10

3.  Long-term control of cystoid macular oedema in noninfectious uveitis with Mycophenolate Mofetil.

Authors:  Piergiorgio Neri; Cesare Mariotti; Luca Cimino; Lucia Mercanti; Alfonso Giovannini
Journal:  Int Ophthalmol       Date:  2008-02-23       Impact factor: 2.031

4.  Inhibition of respiratory syncytial virus replication and suppression of RSV-induced airway inflammation in neonatal rats by colchicine.

Authors:  Nihong Lu; Yongrui Yang; Honglu Liu; Xiangli Ding; Yangbing Ou; Jiawei Xia; Yingrong Du
Journal:  3 Biotech       Date:  2019-10-10       Impact factor: 2.406

5.  Association of systemic steroids and mycophenolate mofetil as rescue therapy for uveitic choroidal neovascularization unresponsive to the traditional immunosuppressants: interventional case series.

Authors:  Piergiorgio Neri; Mara Manoni; Cinzia Fortuna; Marta Lettieri; Cesare Mariotti; Alfonso Giovannini
Journal:  Int Ophthalmol       Date:  2009-09-02       Impact factor: 2.031

6.  Effects of colchicine on renal fibrosis and apoptosis in obstructed kidneys.

Authors:  Sejoong Kim; Eun Sook Jung; Jeonghwan Lee; Nam Ju Heo; Ki Young Na; Jin Suk Han
Journal:  Korean J Intern Med       Date:  2017-03-18       Impact factor: 2.884

Review 7.  Introducing variability in targeting the microtubules: Review of current mechanisms and future directions in colchicine therapy.

Authors:  Esther Forkosh; Ariel Kenig; Yaron Ilan
Journal:  Pharmacol Res Perspect       Date:  2020-08

8.  The effectiveness of colchicine combined with mitomycin C to prolong bleb function in trabeculectomy in rabbits.

Authors:  Taiki Kokubun; Kotaro Yamamoto; Kota Sato; Takahiro Akaishi; Atsushi Shimazaki; Masatsugu Nakamura; Yukihiro Shiga; Satoru Tsuda; Kazuko Omodaka; Toru Nakazawa
Journal:  PLoS One       Date:  2019-03-19       Impact factor: 3.240

9.  p38 MAPK activity is associated with the histological degree of interstitial fibrosis in IgA nephropathy patients.

Authors:  Jeonghwan Lee; Jung Nam An; Jin Ho Hwang; Hajeong Lee; Jung Pyo Lee; Sung Gyun Kim
Journal:  PLoS One       Date:  2019-03-21       Impact factor: 3.240

10.  Predictive usefulness of urinary biomarkers for the identification of cyclosporine A-induced nephrotoxicity in a rat model.

Authors:  Carla Patrícia Carlos; Nathália Martins Sonehara; Sonia Maria Oliani; Emmanuel A Burdmann
Journal:  PLoS One       Date:  2014-07-29       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.